These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36464738)

  • 1. Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease.
    Schwenger KJP; Alali M; Ghorbani Y; Fischer SE; Jackson TD; Okrainec A; Allard JP
    Obes Surg; 2023 Jan; 33(1):247-255. PubMed ID: 36464738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.
    Alqahtani SA; Golabi P; Paik JM; Lam B; Moazez AH; Elariny HA; Goodman Z; Younossi ZM
    Obes Surg; 2021 May; 31(5):2002-2010. PubMed ID: 33616848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease.
    de Carli MA; de Carli LA; Correa MB; Junqueira G; Tovo CV; Coral GP
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):420-425. PubMed ID: 31464779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
    Codjia T; Rebibo L; François A; Lagnel C; Huet E; Bekri S; Pattou F; Régimbeau JM; Schwarz L
    Obes Surg; 2021 Aug; 31(8):3548-3556. PubMed ID: 33844174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between non-invasive methods and liver histology to stratify liver fibrosis in obese patients submitted to bariatric surgery.
    Didoné Filho CN; Reginatto CJ; Ivantes CAP; Strobel R; Percicote AP; Petenusso M; Sobreira da Silva CJR; Benjamim CJR; Radominski RB
    Obes Res Clin Pract; 2021; 15(2):152-156. PubMed ID: 33648885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study.
    Huang Y; Dong S; Wang C; Dong Z; Chen W
    Front Endocrinol (Lausanne); 2023; 14():1090598. PubMed ID: 36793287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIB-4 Reliability in Patients With Severe Obesity: Lower Cutoffs Needed?
    Green V; Lin J; McGrath M; Lloyd A; Ma P; Higa K; Roytman M
    J Clin Gastroenterol; 2024 Sep; 58(8):825-829. PubMed ID: 37983815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
    Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
    Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic utility of FIB-4 as a non-invasive tool for liver fibrosis scoring among NAFLD patients: a retrospective cross-sectional study.
    Amer J; Alnees M; Salameh M; Daraghmeh A; Kabha A; AlHabil Y; Darwish A; Najajra D; Awwad M; Abu Hamdeh N; Abdoh Q
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3104-3111. PubMed ID: 38708469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.